Young Woo Park,Ki Won Jo,Donghee Lee,Eun Kyung Lee,Seil Jang,Chan Woong Park,Dong-Jin Kim,Hye Nan Kim,Yun Jung Park,Jae Eun Park,Ji Hyun Park,Seok Ho Yoo,Myeoung Hee Jang
申请号：
US14009037
公开号：
US20140072558A1
申请日:
2012.04.03
申请国别(地区):
US
年份:
2014
代理人:
摘要：
The present invention relates to an activin receptor type II B (ACVR2B) inhibitor which comprises the delta-like 1 homolog (DLK1) extracellular water-soluble domain. More specifically, the present invention relates to an extracellular soluble domain of DLK1 fragments of the extracellular soluble domain of DLK1 mutants of the extracellular soluble domain of DLK1 a composition for suppressing ligand linkage with the ACVR2B receptor, which includes a fragment of the mutants as an active ingredient and a pharmaceutical composition for prevention and treatment of diseases which comprises the same. The composition of the present invention competitively binds to the ACVR2B receptor and inhibits the binding of an ACVR2B ligand to the ACVR2B receptor, which inhibits protein signalling associated with such ligands, and will be useful for prevention and treatment of diseases associated therewith.
